X

Trial Profile

Safety and Efficacy of Levosimendan in Patients With Acute Myocardial Infarction Complicated by Symptomatic Left Ventricular Failure.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 10 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Levosimendan (Primary)
Indications Decompensated heart failure; Myocardial infarction
Focus Biomarker; Pharmacodynamics
Acronyms LEAF

Most Recent Events

29 Aug 2012 Primary endpoint 'Wall-motion-score' has been met according to results presented at the ESC Congress 2012: Annual Congress of the European Society of Cardiology.
29 Aug 2012 Results presented at the ESC Congress 2012: Annual Congress of the European Society of Cardiology.
25 Jun 2012 Actual end date (Mar 2012) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com